Coherus Oncology Total Debt Growth & History (CHRS)

Coherus Oncology's total debt was $3.3M for fiscal 2025.

View full Coherus Oncology company overview

Coherus Oncology annual total debt history

Coherus Oncology annual total debt

Fiscal yearPeriod endedTotal debtChangeGrowth
20252025-12-31$3.3M−$1.7M−34.00%
20242024-12-31$5.0M−$2.5M−33.40%
20232023-12-31$7.5M−$1.9M−20.19%
20222022-12-31$9.4M−$1.4M−12.84%
20212021-12-31$10.7M−$2.3M−17.87%
20202020-12-31$13.1M−$73.0M−84.81%
20192019-12-31$86.1M$86.1M
20182018-12-31$0
20132013-12-31$1.1M

Coherus Oncology total debt trends

Over the last five fiscal years, Coherus Oncology's total debt decreased from $13.1M to $3.3M, a change of −$9.8M. The latest reported quarter, Q2 2026, shows $2.4M.

About the metric

What total debt means

Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.

Calculation and source

SEC-reported and combined total debt

TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Coherus Oncology source filings ↗

Community posts

It’s quiet here.

No posts about CHRS yet. Start the conversation.

Write the first post